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Background: Both apoptosis and autoantibodies are important factors associated with disease activity in the
pathogenesis of systemic lupus erythematosus (SLE). This study tested the hypothesis that increased leukocyte
apoptosis is associated with elevated levels of autoantibodies and the disease activity of SLE.
Methods: Leukocyte apoptosis was determined by flow cytometry, including annexin V, APO2.7, and
7-amino-actinomycin D (7-AAD) on each subtype of leukocyte in 23 patients with SLE. Leukocyte apoptosis was
also evaluated in nine patients with Sjogren’s syndrome (SJS) and in 20 volunteer subjects. Titers of common
autoantibodies and the disease activity index (SLEDAI-2 k) of the SLE patients were also determined.
Results: Except for annexin V and APO 2.7 of monocytes and late apoptosis (annexin V + 7-ADD) of lymphocytes,
apoptosis in the total and in subsets of leukocytes were significantly higher in SLE patients than in controls
(all p < 0.05, post hoc analysis). The mean percentage of late apoptosis of leukocytes (annexin V + 7-AAD) positively
correlated with levels of anti-Ro52/60 (r = 0.513, p < 0.01), anti-La (r = 0.439, p = 0.04), and anti-Mi-2 (r = 0.492,
p = 0.02), and inversely correlated with both C3 and C4 levels, although not statistically significant. The percentage
of APO2.7 of CD19+ cells positively correlated with SLEDAI-2 K score (p = 0.01).
Conclusions: Leukocyte apoptosis is significantly higher in patients with SLE and correlates well with the levels of
several autoantibodies. The APO2.7 of B-lymphocyte (CD19+) cells positively correlates with the disease activity of
SLE.
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Systemic lupus erythematosus (SLE) is a chronic systemic
disease affecting mostly women of child-bearing age. It is
the prototype of autoimmune diseases because of the var-
iety of proposed pathogenesis. Dozens of autoantibodies
are linked with SLE patients, including some that are
diagnostic and specific [1-3], such as anti-double stranded
deoxyribonucleic acid antibody (a-dsDNA), anti-Smith anti-
body (a-sm), and anti-ribosomal P (a-rib p). The disease* Correspondence: chlu99@ms44.url.com.tw
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reproduction in any medium, provided the oractivity of SLE has also been associated with these
autoantibodies.
Apoptosis is one of several important mechanisms in-
volved in the pathogenesis of SLE. A previous study has
demonstrated that lymphocyte apoptosis is increased
and removal of apoptotic cells is impaired in SLE. Fur-
thermore, apoptosis is higher in active SLE compared to
inactive SLE [4].
Several lines of evidence demonstrate the close rela-
tionship of apoptosis and autoantibodies. Delayed clear-
ance of apoptotic residue, such as histone H3 [5], may
result in the activation of antigen-presenting cells and
the formation of autoantibodies [6,7]. The antigenicity of
autoantibodies is mostly against apoptotic cells, whichThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ies link lymphocyte apoptosis with titers of autoanti-
bodies [9,10], but little is mentioned regarding leukocyte
apoptosis. The present study focuses on SLE patients
due to this lack of detailed data.
To date, little is known about the relationship
among leukocyte apoptosis, levels of autoantibodies,
and severity of SLE. With the hypothesis that in-
creased leukocyte apoptosis is associated with ele-
vated levels of autoantibodies and disease activity of
SLE, this prospectively-designed study aimed to re-
port on the relationship among percentage of




Twenty-three patients with definitive diagnosis of
SLE and followed-up at the Rheumatology Out-
patient Clinic for more than 6 months were prospect-
ively evaluated. The diagnostic criteria for SLE were
based on the 1997 revision of 1982 American College
of Rheumatology (ACR) classification criteria for SLE
[3], while the clinical assessment of disease activity of
SLE was according to the SLE disease activity index
(SLEDAI-2 K) [11]. For comparison, 20 age- and sex-
matched healthy subjects year were enrolled as
healthy controls and nine patients with Sjogren’s
syndrome (SJS) were the disease controls. The SJS
patients were diagnosed based on classification cri-
teria for SJS [12].
The Institutional Review Committee on Human
Research approved the study protocol and the participants
provided informed consent. Patients were excluded if they
had autoimmune diseases other than SLE or SJS, or if they
had fever or any infectious disorder that could affect the
WBC count.
Clinical assessments
All of the subjects underwent complete medical
examinations upon enrollment. Biomarkers were also
collected. Since there were no clinical practice guide-
lines for SLE flare-up, the important decision in
immuno-suppressant adjuvant treatment was whether
or not to add a cytotoxic or corticosteroid-sparing
drug like cyclophosphamide, methotrexate, azathio-
prine, mycophenolate mofetil, or leflunomide. Severe
SLE was defined as an SLEDAI-2 K score >12, while
mild-to-moderate SLE was an SLEDAI-2 K score ≤12
[13].
Blood sampling and assessment of leukocyte apoptosis
Blood samples were collected by venipuncture of the
patient’s forearm vein.Flow cytometry assay using APO 2.7 Antibody for detecting
apoptosis
All of the flow cytometry assays were performed within one
hour after blood extraction to ensure that the results were
as close as possible to the in vivo situation. Fixed amounts
of blood were diluted 1:5 with PBS, and 100 μL was stained
with 10 μL of each of the following: fluorescence conju-
gated monoclonal antibodies against CD45-phycoerythrin
(PE)-Cy5 (clone J33), CD61-fluorescein isothiocyanate
(FITC; clone SZ21), and APO 2.7-PE (clone 2.7A6A3;
Immunotech, Marseille, France). These were then titrated
at saturating concentrations.
The CD45-PE-Cy5 antibody reacted with the CD45
family of trans-membrane glycoproteins, expressed on
the surface of all human leukocytes, and a pan-leukocyte
marker. The CD61-FITC antibody was a pan-platelet
marker that reacted with the GPIIb/IIIa complex
(fibrinogen receptor). The APO 2.7-PE antibody reacted
with a 38-kDa mitochondrial membrane protein (7A6
antigen), which was detectable on non-permeabilized
cells in the late apoptotic state [14].
Annexin V staining, relevant to early apoptosis, pro-
duced similar results but was rejected for questionable
reliability under fixation conditions, with formaldehyde
clearly biasing the staining results. Mouse immuno-
globulin G-PE was a control for non-specific staining,
which did not differ from the APO2.7-PE signal on
platelets, such that each subject was its own control
without changing the sample tube. After 30 min of incu-
bation in the dark at room temperature, the stained
samples were diluted with 0.5 ml of FACSFlow (Becton
Dickinson, San Jose, CA).
Flow cytometry analysis was performed immediately
after staining using an Epics XL flow cytometer (Beckman
Coulter, Fullerton, California) and the CellQuest software.
Five thousand CD45-PE-Cy5+ cells per sample were ac-
quired in a combined forward and side scatters and deep-
red FL4 fluorescence (CD45-PE-Cy5) leukocyte gate. An-
other 5000 CD61-FITC + cells per sample were acquired
in a combined forward and side scatters and green FL1
fluorescence (CD61-FITC) platelet gate to define a nega-
tive control threshold for the measurement of apoptosis,
such that each subject was its own control.
Annexin V-FITC 7-AAD fluorescence-activated cell analysis
Membrane phosphatidyl-serine was detected by annexin-V
using a commercially available kit (Boehringer Mannheim,
Indianapolis, Indiana). The PBS-washed leucocytes were in-
cubated with annexin V-FITC and 7-amino-actinomycin D
(7-AAD) for 15 min at room temperature according to
manufacturer’s guidelines. Samples were transferred to
5-mL polypropylene tubes, diluted 900 μL with Hanks’ bal-
anced salt solution, and placed on ice before analysis by
flow cytometry. The samples were analyzed using an Epics
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and the CellQuest software. Fifteen thousand events were
counted per sample. Low-fluorescence debris was gated
out of the analysis. Leukocyte subtypes were identified
according to their CD45 expression intensity and divided
into neutrophils, monocytes, and lymphocytes. From here
on, white blood cells (WBC) represented total leukocytes.
Annexin V-FITC staining was identified in fluorescent-1
and 7-AAD staining in fluorescent-4. Cells were identified
as follows: early apoptotic cells if they were positive for
marker annexin V-FITC but negative for 7-AAD; late
apoptotic cells if they were positive for annexin V-FITC
and 7-AAD; dead cells if they were negative for annexin
V-FITC but positive for 7-AAD; and viable cells if they
were negative for annexin V-FITC and 7-AAD.
Apoptosis of lymphocytes
Fixed amounts of blood were diluted 1:5 with PBS and
100 μL was stained with 10 μL of each of the following:
fluorescence conjugated monoclonal antibodies against
CD4-phycoerythrin (PE)-Cy5, CD19-fluorescein isothio-
cyanate (FITC), and CD8- phycoerythrin (PE). Each of
the above staining was further stained with annexin V-
FITC, 7-amino-actinomycin D (7-AAD), or APO 2.7-PE
(clone 2.7A6A3; Immunotech, Marseille, France). These
were then titrated at saturating concentrations. Samples
were transferred to 5-mL polypropylene tubes, diluted
with 900 μL of Hanks’ balanced salt solution, and placed
on ice before flow cytometry. Samples were analyzed
using an Epics XL flow cytometer (Beckman Coulter,
Fullerton, California) and the CellQuest software. Fifteen
thousand events were counted per sample. Lymphocyte
subtypes were identified according to their surface anti-
gen (i.e., CD4, CD8, or CD19) expression intensity. A
database coordinator was responsible for monitoring all
data collection and entry.
Autoantibody detection
Autoantibody titers, including IgG antibodies against
dsDNA (a-dsdna), Ribosomal p (a-ribp), Ro (52/60) (a-ro),
Ro 52 kDa (a-ro52), Ro 60 kDa (a-ro60), La (a-la), U1RNP
(a-u1rnp), Sm (a-sm), and Mi-2 (a-mi2) were detected by
Elia-Phadia 250 according to the operation manual. All
data were checked for any inconsistencies. Intra-assay
variability based on repeated measurements of the same
blood sample was low, with mean coefficients of variance
between 6.11% and 14.28% for SLE patients, and 6.0% in
control individuals.
Statistical analysis
Data were expressed as mean ± SD or median (inter-quar-
tile range). Categorical variables were compared using
Chi-square test or Fisher’s exact test, as appropriate. The
percentage of leukocyte apoptosis and autoantibody levelwere logarithmically transformed to improve normality.
Univariate analyses were compared using Student’s t-test.
Continuous variables among the three groups (SLE, SJS,
and volunteer control) were compared using one-way
ANOVA, followed by Bonferroni post hoc multiple com-
parison procedure. Correlation analysis was used to evalu-
ate the relationship among mean SLEDAI-2 K score,
percentage of leukocyte apoptosis, and levels of autoanti-
bodies. Statistical significance was set at p < 0.05. Receiver
operating characteristic (ROC) curves were generated
for leukocyte apoptosis. The areas under the ROC
curves (AUC) were calculated for each parameter and
compared. All statistical calculations were performed
using the SAS software package, version 9.1 (2002, SAS
Statistical Institute, North Carolina).
Results
Baseline characteristics of the study patients
The baseline characteristics and laboratory data of SLE
patients, SJS patients, and control groups, as well as their
medications, were listed in Table 1. Although the mean
age was older in the SJS group, there was no statistically
significant difference in age and sex among the three
groups (p = 0.16 and p = 0.541, respectively). The clinical
symptoms of the 23 SLE patients included musculo-
skeletal involvement in 15, neurologic involvement in 14,
muco-cutaneous involvement in two, hematologic in-
volvement in six, cardio-respiratory involvement in two,
and renal involvement in two. The clinical symptoms of
the nine patients with SJS were also listed.
Leukocyte apoptosis in patients with SLE, patients with
SJS, and the controls
The laboratory data and percentage of leukocyte apoptosis
of the three groups were listed in Table 2. Except for
hemoglobin level, the WBC and platelet counts were not
significantly different among the three groups. Except for
annexin V and APO2.7 in monocytes and annexin V +
7AAD in lymphocytes, the percentages of apoptosis of
total leukocytes and the leukocyte subsets were signifi-
cantly higher in the SLE patients than in the controls.
Correlation of clinical severity, autoantibody level, and
percentage of leukocyte apoptosis
Regarding the innate immune cells, the mean percentages
of late apoptosis of leukocyte (annexin V-FITC and
7-AAD) positively correlated with levels of anti-dsDNA
(r = 0.415, p < 0.05), anti-Ro52/60 (r = 0.513, p < 0.01),
anti-La (r = 0.439, p = 0.04), anti-Mi-2 (r = 0.492, p = 0.02),
and inversely correlated with both C3 and C4 levels, al-
though not statistically significant (Table 3). The SLE dis-
ease activity index (SLEDAI-2 K) positively correlated
with anti-Ro 60 kDa (r = 0.407, p = 0.05), but negatively
correlated with complement C4 level (r = -0.508, p = 0.01).
Table 1 Baseline characteristics of SLE patients, SJS patients, and control subjects
SLE patients Sjogren's syndrome Healthy controls
(n = 23) (n = 9) (n = 20)
Age (y) (mean ± SD) 44.38 ± 10.87 56.56 ± 13.86 48.37 ± 12.01
Male /female 2/21 1/8 6/14
Clinical symptoms Ϯ
Constitutional 9 0 —
Muco-cutaneous involvement 2 0 —
Neurological involvement 14 7 —
Musculo-skeletal involvement 15 2 —
Cardio-respiratory involvement 2 0 —
Renal involvement 3 0 —
Hematologic involvement 6 0 —
Median (IQR) SLEDAI-2 K 11 (6-14) —
Mean dosage of medication (mg/day) ξ ᶃ
Prednisolone 21 (mg/day) (n = 15) 3.3 (mg/day) (n = 5) —
Hydroxychloroquine 300 (mg/day) (n = 17) 150 (mg/day) (n = 5) —
Azathioprine 50 (mg/day) (n = 1) 0 —
Mycophenolate 1080 (mg/day) (n = 1) 0 —
Cyclophosphamide 500 (mg/month) (n = 2) 0 —
Cyclosporine 50 (mg/day) (n = 3) 0 —
Ϯ17 patients who had more than one clinical symptom.
ξ12 patients who took more than one medication.
ᶃ4 patients who took more than one medication.
Abbreviations: SLE Systemic lupus erythematosus, SJS Sjogren’s syndrome, IQR Inter-quartile range, SLEDAI-2 K Systemic lupus erythematosus disease activity
index 2000.
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CD4 (+) cell apoptosis in APO2.7 negatively correlated with
anti-Ro 52 kDa (r = -0.717, p = 0.03), and anti-Ro52/60
(r = -0.684, p = 0.04). The percentage of CD19 (+) cell
apoptosis in APO2.7 positive correlated with SLE disease
activity index (SLEDAI-2 K) (r = 0.793, p = 0.01), but
negative correlated with a-dsDNA (r = -0.883, p < 0.001).
Furthermore, the AUC for the percentage of APO2.7 in
B-lymphocyte (CD19+) apoptosis was 0.95 (p = 0.027,
95% CI: 0.00-1.00). The cut-off value of the percentage of
APO2.7 in B-lymphocyte (CD19+) apoptosis for severe
SLE was 1.01% (sensitivity 75% and specificity 95%). Other
results were listed in Table 3.
Discussion
The present study has several major findings. First, the
percentage of leukocyte apoptosis (including neutrophil,
monocyte, and lymphocyte apoptosis) is significantly
higher in SLE patients than in healthy controls. Second,
the mean percentages of late apoptosis of leukocyte
(annexin V + 7-AAD) positively correlate with levels of
most common autoantibodies (e.g. anti-Ro52/60, anti-La,
and anti-Mi-2). Third, the percentage of CD4 (+) cell
apoptosis in APO2.7 significantly but negatively correlates
with levels of several autoantibodies (e.g. anti-Ro52/60,and anti-Ro52kDa). Fourth, the level of C3 negatively
correlates with the late apoptosis of granulocyte (7-
AAD + annexin V). The level of C4 positively correlates
with the late apoptosis (7-AAD + annexin V) of CD8
cells. Lastly, the percentage of APO2.7 on B-lymphocyte
(CD19+) apoptosis significantly correlates with median
SLEDAI-2K score. The cut-off value of 1% of APO2.7
on B-lymphocyte (CD19+) apoptosis is associated with
severe SLE. APO2.7 is expressed on the mitochondrial
membrane during early apoptosis in relation to the re-
lease of cytochrome c and represents the activation-
induced cell death under certain circumstances [15,16].
Several lines of blood cells have defects in the apop-
tosis pathway in SLE patients, either prone or resistant
to apoptosis [17-23]. Some studies reveal increased
monocyte and lymphocyte apoptosis [18,20,21,23], but
other studies demonstrate increased leukocyte apoptosis
[22], and decreased B-lymphocyte apoptosis [17] or no
difference in apoptosis [19]. Generally speaking, in the
present study, the percentages of apoptosis in most
leukocyte subsets, including neutrophils, monocytes, and
lymphocytes, are significantly higher in SLE patients
than in controls.
Leukocyte late apoptosis markers are positively corre-
lated with levels of several autoantibodies, including
Table 2 Laboratory data of the SLE patients and control subjects
SLE patients SJS patients Healthy controls p
value(n = 23) (n = 9) (n = 20)
White blood cells (×103/ml) 6.73 ± 2.5 6.47 ± 1.97 5.68 ± 1.89 0.442
% granulocyte 69.49 ± 13.19 65.93 ± 10.22 61.6 ± 12.76 0.341
% lymphocyte 22.81 ± 11.65 25.33 ± 9.15 31.01 ± 10.85 0.232
% monocyte 5.57 ± 3.00 6.19 ± 2.44 5.63 ± 1.74 0.873
Hemoglobulin (mg/dL) 11.73 ± 1.73 12.38 ± 0.99 14.06 ± 1.86 0.003α
Platelet counts (×104/ml) 22.13 ± 8.49 23.67 ± 5.39 22.26 ± 6.19 0.851
Autoantibodies titers
a-dsdna 18 (1.7, 70.0) ND ND ND
a-ro 0.5 (0.1, 240) 84.75 (0.3, 217.5) ND 0.725
a-ro52 0.3 (0.1, 32) ND ND ND
a-ro60 0.9 (0, 300) ND ND ND
a-la 0.2 (0, 3.3) 0.2 (0.1, 4.45) ND 0.896
a-mi2 0.1 (0, 0.2) ND ND ND
Apoptosis tested by flow cytometry?
Leukocyte apoptosis (%)
Annexin V (%) 15.3 (8.9-18.2) 9.87 (8.29-12.50) 10.9 (8.8-13.4) 0.005β
APO2.7 (%) 1.3 (0.9-2.2) 1.10(0.70-1.57) 0.7 (0.5-0.9) 0.001γ
Annexin V + 7AAD (%) 7.1 (3.8-11.8) 6.58(2.80-10.10) 3.2 (2.6-4.5) 0.011δ
Neutrophil apoptosis (%)
Annexin V (%) 21.6 (11.7-28.8) 9.15 (7.80-15.76) 13.9 (10.3-18.0) 0.010ε
APO2.7 (%) 0.6 (0.4-1.3) 0.79(0.40-1.05) 0.5 (0.4-0.6) 0.001ζ
Annexin V + 7AAD (%) 10.7 (3.1-22.8) 6.93(1.97-20.60) 3.9 (2.2-5.5) 0.026η
Lymphocyte apoptosis (%)
Annexin V (%) 8.4 (4.9-12.1) 6.10 (5.11-8.23) 4.8 (3.8-6.7) 0.009θ
APO2.7 (%) 0.7 (0.5-1.0) 0.46(0.43-0.78) 0.3 (0.2-0.4) 0.008κ
Annexin V + 7AAD (%) 2.1 (1.2-3.6) 1.46(0.67-2.92) 1.5 (0.9-2.1) 0.101
Monocyte apoptosis (%)
Annexin V (%) 19.6 (13.5-27.3) 13.83 (11.42-15.38) 17.4 (12.4-21.6) 0.032λ
APO2.7 (%) 3.0 (2.5-6.8) 1.94 (1.48-3.27) 1.8 (1.1-2.7) 0.088
Annexin V + 7AAD (%) 10.4 (5.3-17.8) 7.63 (3.34-15.36) 4.6 (3.3-6.0) 0.024μ
Abbreviations: SLE Systemic lupus erythematosus, SJS Sjogren’s syndrome, WBC White blood cells or leukocytes, 7-AAD 7-amino-actinomycin D, SD Standard
deviation, IQR Inter-quartile range, A-dsdna Anti-dsDNA, A-ro Anti-Ro52/60, A-ro52 Anti-Ro 52 kDa, A-ro60 Anti-Ro 60 kDa, A-la Anti-La, ND Not done.
ϮFigures are median (IQR) or number (%).
Results of Bonferroni multiple comparisons for post hoc test (SLE vs. control, SLE vs. SJS, or SJS vs. control).
α, SLE vs. control = 0.002; β, SLE vs. control = 0.014, SLE vs. SJS = 0.029; γ, SLE vs. control = 0.001; δ, SLE vs. control = 0.009; ε, SLE vs. control = 0.005, SLE vs.
SJS = 0.004; ζ, SLE vs. control = 0.041; η, SLE vs. control = 0.021; θ, SLE vs. control = 0.008; κ, SLE vs. control = 0.007; λ, SLE vs. SJS = 0.036; μ, SLE vs. control = 0.026.
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between leukocyte apoptosis and antibody formation, as
previously proposed [24,25].
The CD4 (+) cell apoptosis marker APO2.7 is negatively
correlated with levels of anti-Ro52, and anti-Ro. Since the
anti- Ro antibody is elevated in many patients with lupus
[26], CD4 (+) cell apoptosis may be decreased in SLE
patients. The present study demonstrates that the APO2.7
of CD19+ lymphocytes is positively correlated with
disease activity index. Several studies have demonstratedthat the appearance of APO2.7 on lymphocytes represents
activation and elevated titers of autoantibodies [16,27].
However, activated APO2.7 on lymphocytes may be re-
versed by downstream anti-apoptosis molecules, as shown
in other studies [15,28]. Lastly, increased activated
APO2.7 of CD19+ lymphocytes may undergo apoptosis
after immuno-suppressant therapy [29]. Thus, in this
study, activation through a mitochondria-dependent path-
way among CD19+ lymphocytes is prominent in patients
with active SLE. Disease activity is positively correlated
Table 3 Correlation among apoptotic markers, disease activity, and levels of autoantibodies in lupus patients
SLEDAI2k c3 c4 a-ro a-ro52 a-ro60 a-la a-mi2
(7AAD + annexinV) of WBC (%) r 0.14 -0.3 -0.19 .513* 0.29 0.41 .439* .492*
p value 0.54 0.17 0.39 0.01 0.17 0.05 0.04 0.02
(7AAD + annexinV) of Granulocyte (%) r 0.18 -.460* -0.2 0.33 0.2 0.32 0.33 0.3
p value 0.42 0.03 0.37 0.13 0.36 0.13 0.13 0.16
(7AAD + annexinV) of CD8 (+)(%) r -0.06 0.35 .636* -0.07 0.07 -0.21 -0.09 -0.11
p value 0.87 0.33 0.04 0.85 0.85 0.57 0.8 0.77
APO2.7 of CD4(+)(%) r 0.3 0.17 0.05 -.684* -.717* -0.62 -0.57 -0.24
p value 0.43 0.67 0.9 0.04 0.03 0.08 0.11 0.54
APO2.7 of CD19 (+)(%) r .793* -0.45 -0.48 0.32 0.34 0.29 0.4 -0.07
p value 0.01 0.22 0.19 0.4 0.37 0.45 0.28 0.86
SLEDAI2k r X -0.35 -.508* 0.3 0.23 .407* 0.24 0.21
p value 0.1 0.01 0.15 0.29 0.05 0.25 0.32
Note: *, p<0.05.
Abbreviations: R Correlation coefficient, A-ro Anti-Ro52/60, A-ro52 Anti-Ro 52 kDa, A-ro60 Anti-Ro 60 kDa, A-la Anti-La, A-mi2 Anti-Mi-2, WBC White blood cells or
leukocytes, 7-AAD 7-amino-actinomycin D, SLEDAI-2 K Systemic lupus erythematosus disease activity index 2000.
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tioned in other investigations [1,2].
During SLE flare-up, both C3 and C4 are decreased, so
the late apoptosis of granulocyte increases [30] but the
apoptosis of CD8 (+) cells decreases. The present study
also demonstrates that the level of C3 is significantly but
negatively correlated with the late apoptosis of granulocyte
(7-AAD+ annexin V), while the level of C4 is positively
correlated with the late apoptosis (7-AAD+ annexin V) of
CD8 cells (Table 3). Linker-Israeli et al. have shown that
CD8 (+) cells participate in autoantibody synthesis in
SLE [31].
There are significant differences of apoptosis markers in
annexin V of leukocytes (SLE vs. SJS, p = 0.029), neutro-
phils (SLE vs. SJS, p = 0.004), and monocytes (SLE vs. SJS,
p = 0.036) during the post hoc analysis, despite no dif-
ference in absolute numbers of leukocytes, neutrophils,
and monocytes between SLE and SJS patients. Similarly,
Armstrong et al [22] demonstrated higher annexin V of
neutrophils among SLE patients compared to those with
other autoimmune diseases, while Bengtsson et al [21]
demonstrated higher annexin V of monocytes. These find-
ing suggest that there are more autoantigens, which may
the induce apoptosis of leukocytes, in SLE patients than
in the disease controls.
This study has several limitations. First, there are many
assays for evaluating apoptosis in vitro so the results and
interpretations from various methodologies may be par-
tially different. The level of apoptosis tested by flow cy-
tometry may not necessarily reflect the real leukocyte
physiologic function in vivo. Similar protocols are used to
detect cell apoptosis [29,32,33]. Second, this is a cross-
sectional observational study. Theoretically, high-dose
immuno-suppressant drugs can affect leukocyte activityand autoantibody levels. Although the dosages of
steroids (mean, 31 mg/day) and hydroxychloroquine
(mean, 300 mg/day) used in this case control study are
not high, their effects still cannot be excluded. Lastly,
the case number in this study is not large and similar
aspects of results have been obtained from other series
studies with small case numbers [34,35]. Large-scale
prospective and longitudinal studies are needed to
evaluate the prognostic contribution of leukocyte apop-
tosis on clinical outcome.
In conclusion, leukocyte apoptosis is significantly higher
in SLE patients and correlates well with the levels of several
autoantibodies. The APO2.7 of B-lymphocyte (CD19+)
cells positively correlates with the disease activity of SLE.Ethical approval
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